Retinitis pigmentosa (RP) is a group of inherited genetic disorders characterized by progressive peripheral vision loss and night vision difficulties followed by eventual central vision loss and blindness in many cases. RP is typically diagnosed in adolescents and young adults. The rate of progression and degree of visual loss varies from person to person.

Approximately 100,000 people living in the US and between 0.03% and 0.04% of the global population suffer from RP. An estimated 25,000 people in the US with RP have progressed to a more advanced form of the disease and are legally blind with 20/200 or worse vision. Currently, there are no FDA approved therapies for the prevention or treatment of RP.

RetroSense will pursue RP as a lead indication for RST-001 and seek orphan drug status.

Dry AMD occurs when the light-sensitive cells in the macula break down, gradually blurring central vision. The macula is located in the center of the retina, the light-sensitive tissue at the back of the eye. Over time, as more photoreceptors in the macula atrophy and die, central vision is lost.

Dry AMD is most common type of macular degeneration and affects 90% of the people with AMD.

Advanced dry AMD, or geographic atrophy, is characterized by progressive loss of photoreceptors causing profound vision loss and in some cases, blindness. Nearly 1 million people in the US suffer from advanced dry AMD. Of them, an estimated 200,000 people with advanced dry-AMD are legally blind and suffer from 20/200 vision or worse.

Currently there are no FDA approved therapies for the prevention or treatment of dry AMD.

RetroSense will pursue Advanced Dry-AMD as a second indication for RST-001.